I'm not trying to make any guesses about how we might be able to change the outcomes for the women affected, but what happens at a decision-making level around who is digging into the research, and who is making recommendations around allocating budgets in certain areas? Could better federal GBA get at any of those issues, or is something more fundamental at play when we see such discrepancies, especially in this case, for a disease that only women are ever going to encounter?
On May 17th, 2016. See this statement in context.